NFKBIA and chronic myelogenous leukemia, BCR-ABL1 positive: Previous evidences illustrate that RPL32 plays an important role in the SF3B1 mutation for chronic myeloid leukemia (CML) disease progression [43], CD52 helps identify molecular signature of CML [44] and NFKBIA plays a strategic role in CML molecular response [45].